Cortagen vs Cartalax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed at the St. Petersburg Institute of Bioregulation as a cardioprotective and vascular bioregulator. It stimulates repair of cardiac and vascular tissue, with demonstrated benefits for coronary artery disease, atherosclerosis, and cardiac aging.
- Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
- Half-Life
- Short peptide half-life; gene regulatory effects persist beyond peptide clearance
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- SubQ, IM, Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 10 mg SC or IM daily
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Cardioprotective — protects cardiac tissue from ischemic damage
- Promotes cardiac regeneration and repair
- Improves vascular endothelium function
- Reduces atherosclerosis progression
- Anti-aging effect on heart muscle cells
- Improves cardiac output and exercise capacity
- Reduces oxidative stress in cardiovascular tissue
- May reduce arrhythmia frequency
- Supports cartilage matrix synthesis and maintenance
- May slow progression of osteoarthritic cartilage degradation
- Reduces chondrocyte apoptosis
- Promotes joint longevity in aging and high-impact sports
- Anti-aging effects on connective tissue
- Complementary to BPC-157 and TB-500 in joint recovery protocols
- Well tolerated in available human and animal research
- Side Effects
- Excellent safety profile
- Mild injection site reactions
- Rare: transient hypotension
- Rare: mild arrhythmia at initiation in cardiac patients
- Generally well tolerated
- Mild injection site reactions
- No significant adverse events reported at standard doses
- Stacks With
- —
- —